Securities Class Action Filed Against Aerie Pharmaceuticals, Inc.
Violations of federal securities laws as a result of a series of materially false statements. The Complaint alleges that, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose adverse information regarding the Company’s prospects for its lead product candidate, RhopressaTM (“Rhopressa”). On April 23, 2015, the Company issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa. According to the release, “[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.” On this news, shares of Aerie fell $22.52 per share, to close at $12.87 per share on April 24, 2015. Filed in D.N.J.
Lead Plaintiff Deadline: The deadline to file for lead plaintiff in this action is 6/29/2015.
Join This Action: To apply to join this action and be represented by Shepherd, Finkelman, Miller & Shah, LLP, please click here for a certification form to submit your information.
Send Us Information: If you have information about this action that you would like to provide us, please click here.